Show simple item record

dc.contributor.authorLoh, N. R.
dc.contributor.authorWhitehouse, W. P.
dc.contributor.authorHowells, R.
dc.identifier.citationArch Dis Child. 2022 Feb 21:archdischild-2021-322373. doi: 10.1136/archdischild-2021-322373.
dc.description.abstractFor this narrative review, we found recent publications on the use and effectiveness of old therapies including nutraceuticals, such as riboflavin, vitamin D, magnesium, melatonin and talking therapies. Recent large trials of established conventional pharmaceuticals such as propranolol, pizotifen, topiramate and amitriptyline for childhood migraine have failed, but the use of a quasi-placebo in future trials could help. We reviewed the evidence for angiotensin antagonists including candesartan in adults, but found a lack of evidence for their use in children. There have been new developments in pharmaceuticals recently, including a more selective 5-HT1F agonist, lasmiditan, an effective acute treatment with no vasoconstrictor activity in adults, currently being tested in children. Also, a number of new calcitonin gene-related peptide (CGRP) antibodies and antagonists, with proven efficacy in acute treatment and/or prevention of migraine in adults, are undergoing trials in children. Peripheral nerve blocks and botulinum toxin are gaining popularity in adult practice, but we really need more good quality evidence for their effectiveness in children. Finally, electroceuticals, that is, therapeutic electric devices, are now marketed for acute and or preventative treatment, including an external trigeminal nerve stimulator (e-TNS), a non-invasive vagal nerve stimulator (nVNS), a single-pulse transcranial magnetic stimulator (sTMS) and a remote electrical neuromodulation device (REN). At the moment, evidence for their effectiveness in children is still lacking. So, there has been much progress, but mostly for adults. We are in urgent need of more migraine trials in children.
dc.rights© Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.
dc.subjectadolescent health
dc.titleWhat is new in migraine management in children and young people?
dc.typeJournal Article
dc.identifier.journalArchives of disease in childhood
dc.description.noteRD&E staff can access the full-text of this article by clicking on the 'Additional Link' above and logging in with NHS OpenAthens if prompted.
dc.description.admin-notePublished version, accepted version, submitted version

Files in this item


There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record